The disclosure provides methods of treating cancer comprising administering to a subject in need thereof a cytokine engager in combination with a T cell engaging molecule, an engineered T cell expressing a CAR or a TCR, or a bispecific binding protein that specifically binds to PD-1 and TIGIT, wherein the cytokine engager comprises an antibody that specifically binds human CD8, and wherein the antibody is fused to a cytokine (e.g., IL-2).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The specification relates to conjugates comprising one or more tubulin inhibiting moieties DM and pharmaceutically acceptable salts thereof. The specification also relates the use of the conjugates for the treatment of diseases such as cancer, and intermediates useful for the synthesis of the conjugates.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure, relates, in general, to methods of treating chronic rhinosinusitis, with or without nasal polyps, using an antibody specific for thymic stromal lymphopoietin (TSLP).
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present specification relates to compounds, and pharmaceutically acceptable salts thereof, that inhibit the growth of cancers that express G13D mutant Ras proteins. The molecules of the specification are thus indicated for use in the treatment of Ras G13D mutant cancers and for use in methods for the treatment of Ras G13D mutant cancers.
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
The specification relates to a compound of Formula (I) and salts thereof, useful for synthesis of antibody conjugates comprising a microtubule inhibitor. The specification also relates to the antibody conjugates, their use in the treatment of cancer, and intermediates of the compound of Formula (I).
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
The specification relates to conjugates comprising a linker of Formula (IA): and pharmaceutically acceptable salts thereof. The specification also relates the use of the conjugates for the treatment of diseases such as cancer, and intermediates useful for the synthesis of the conjugates.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Lipid nanoparticles are provided which comprise a lipid matrix and a GalNAc-containing compound. The nanoparticles are capable of binding to asialoglycoprotein receptors and may thus be used, for example, in the targeted delivery of nucleic acid cargos to cells such as liver cells. Also provided are pharmaceutical compositions comprising the lipid nanoparticles, medical uses thereof, GalNAc-containing compounds per se, and processes for preparing the lipid nanoparticles and GalNAc compounds of the disclosure.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Methods for treating and/or preventing HFpEF and/or at least one disease, disorder, and/or condition associated therewith in patients by the use of dapagliflozin and compositions comprising the same are disclosed.
The present application relates to compounds of formula (A) that inhibit the growth of cancers that express G12D mutant Ras proteins. The molecules of the specification are thus indicated for use in the treatment of cancer that express G12D mutant Ras protein.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
Provided herein are anti-IL5R antibody formulations containing an amount of surfactant below critical micelle concentration (CMC) of the surfactant and methods of using such formulations.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The specification generally relates to compounds of Formula (I), Formula (II) and Formula (VI), and pharmaceutically acceptable salts thereof. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds. (Formula (I) Formula (II) Formula (VI))
The specification generally relates to compounds of Formula (I), Formula (II) and Formula (VI), and pharmaceutically acceptable salts thereof. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds. (Formula (I) Formula (II) Formula (VI))
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
C07D 237/34 - Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
19.
BILIARY TRACT CANCER TREATMENT WITH ANTI-CLAUDIN 18.2 ADC
Provided herein is a method of treating biliary tract cancers in humans. The method uses an antibody-drug conjugate (ADC) comprising an antibody (or antigen-binding fragment thereof) which specifically binds claudin 18.2 (CLDN18.2). The ADC is used for treatment of biliary tract cancers which express CLDN18.2.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided herein is a novel rAAV-based HSV production method that includes two engineered cell lines: engineered CHO cells to produce multiple AAV serotypes and engineered BHK-21 to produce rHSV-1 stocks that are used in the production of rAAVs in CHO cells. The developed method provides a scalable, serum-free manufacturing platform.
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
C12N 15/90 - Stable introduction of foreign DNA into chromosome
The present disclosure relates to therapeutic combinations of capivasertib and fulvestrant that are useful for treating specific populations of patients having advanced breast cancer, and to methods of treating specific populations of breast cancer patients with combinations of capivasertib and fulvestrant.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
The present invention relates to antibodies that inhibit the enzymatic activity of human CD39 and methods of using the compounds to treat cancer, including in combination with an anti-PD(L)1 antibody. The anti-CD39 antibody and the anti-PD(L)1 antibody can be administered as neoadjuvant therapy to treat lung cancer. The invention also relates to dosing regimens for combination treatment with anti-CD39 antibody and an anti-PD(L)1 antibody.
The present specification relates to compounds of formula (I) which are RIPK1 inhibitors, pharmaceutical compositions comprising them and their use as medicaments.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
There is described herein a dry powder inhaler device (100) for administering a powder by inhalation, comprising: a storage chamber operable to hold a supply of powder; a dosing unit (235) adjacent the storage chamber, the dosing unit comprising a rotatable disc with one or more dosing stations, each dosing station comprising less than 5 dosing holes (250) through the rotatable disc, each dosing hole configured to receive and transfer a metered dose of the powder from the storage chamber to an inhalation channel, wherein each of the dosing holes has a side wall profile comprising a curved section; a pressure plate (240) urged against the dosing unit; and an inhalation channel in fluid communication with the dosing unit, wherein the inhalation channel directs the powder entrained in airflow to a user upon inhalation.
Crystalline 6'-([(1S,3S)-3-([5-(difluoromethoxy)-2-pyrimidinyl]amino)cyclopentyl]amino)-2H- [1,3'-bipyridin]-2-one (AZD0780) in form B, a crystalline form comprising AZD0780 and fumaric acid as a co-crystal, a crystalline form comprising AZD0780 and succinic acid as a co-crystal, and a method of making AZD0780 with key intermediates.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A pharmaceutical product for administration of an anti- HER2 antibody-drug conjugate (ADC) in combination with an anti-TROP2 ADC is provided. The anti-HER2 ADC and the anti-TROP2 ADC comprise a drug-linker. An exatecan may be the drug of the drug-linker and the drug-linker may be conjugated to the respective antibody via a thioether bond. Also provided is a therapeutic use and method in which the anti-HER2 ADC and the anti-TROP2 ADC are administered in combination to a subject. The anti-HER2 ADC and anti-TROP2 ADC in combination have excellent anti-cancer properties.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The disclosure relates to methods, compositions, and combinations for the treatment of cancer. Specifically, the disclosure relates to methods comprising administering to a subject in need thereof at least one of an anti-CTLA-4 antibody or an antigen-binding fragment and an anti-PD- L1 antibody or an antigen-binding fragment thereof. The disclosure also relates to combinations comprising at least one of an anti-CTLA-4 antibody or an antigen-binding fragment and an anti- PD-L1 antibody or an antigen-binding fragment thereof.
This disclosure relates to an Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) and an anti-EGFR/cMET antibody molecule for use in combination in the treatment of cancer (for example, non-small cell lung cancer [NSCLC]).
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Provided herein is a method of treating biliary tract cancers in humans. The method uses an antibody- drug conjugate (ADC) comprising an antibody (or antigen-binding fragment thereof) which specifically binds claudin 18.2 (CLDN18.2). The ADC is used for treatment of biliary tract cancers which express CLDN18.2.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present specification relates to pharmaceutical formulations comprising N-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine, microcrystalline cellulose (MCC) and dicalcium phosphate anhydrous (DCPA), for example tablets with immediate release properties.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
The specification relates to compounds of Formula (1):
The specification relates to compounds of Formula (1):
The specification relates to compounds of Formula (1):
and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of diseases such as liver disease.
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The present disclosure relates to methods and dosage regimen for treating or preventing a FAP-mediated condition, comprising administering to the subject a compound of Formula (I), as defined herein, or a pharmaceutically acceptable salt thereof.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present disclosure provides compounds represented by Formula (I), or a pharmaceutically acceptable salt and/or stereoisomer thereof: wherein Ra, Rb, Rc, R7, R8, R9, R10, X3, W, L, and E are as defined in the specification. Compounds represented by Formula (I) are SMARCA2 protein degraders and are thus useful for treating cancer and other diseases.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
The present invention provides a pharmaceutical tablet formulation of tenapanor that is chemically stable and soluble comprising greater than about 6% w/w of amorphous tenapanor in its bis-HCl form, an acidifying agent, an antioxidant, a disintegrant, a lubricant, a glidant, a filler, and an immediate release coating, wherein the total chloride content of the active ingredient is greater than 5.82% and the particle diameter distribution D50 is from about from about 18 μm to about 22 μm.
The specification relates to conjugates comprising one or more DM and pharmaceutically acceptable salts thereof. The specification also relates the use of the conjugates for the treatment of diseases such as cancer, and intermediates useful for the synthesis of the conjugates.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure relates to dosage regimens for the administration of a recombinant apyrase protein and their medical use in the treatment of ischemic events in a patient, such as ST-segment elevation myocardial infarction and acute ischemic stroke.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
60.
CLAUDIN 18.2 ANTIBODIES, ANTIGEN BINDING FRAGMENTS AND ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE IN CANCER THERAPY
Provided are antibodies, antigen binding fragments, and immunoconjugates thereof that specifically bind to claudin 18.2 expressing cells, along with pharmaceutical compositions and kits comprising the antibodies, antigen binding fragments, and/or immunoconjugates. Methods of use of the antibodies, antigen binding fragments, and immunoconjugates in the treatment of claudin 18.2 expressing tumor cells is also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
72.
SYSTEMS AND METHODS FOR END TO END CONTINUOUS DOWNSTREAM PROCESSING
Provided herein are methods of purifying proteins of interest using continuous counter-current downstream processing. Also provided herein are methods of purifying proteins of interest using continuous counter-current affinity nanoparticle dialysis.
The present disclosure relates to methods of treating PTEN-deficient metastatic hormone- sensitive prostate cancer (mHSPC) in patients in need thereof, the methods comprising administering to the patients a combination comprising capivasertib or a pharmaceutically acceptable salt thereof; and abiraterone or an ester prodrug thereof, or a pharmaceutically acceptable salt thereof.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
Disclosed herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, Y1, X2, Y2, a, b, c, d, e and f are as defined herein. Also disclosed are lipid nanoparticles comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a plurality of lipid nanoparticles comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a nucleic acid segment; as well as methods for delivering a nucleic acid segment comprising administering a plurality of lipid nanoparticles comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a nucleic acid segment.
Disclosed herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, Y1, X2, Y2, a, b, c, d, e and f are as defined herein. Also disclosed are lipid nanoparticles comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a plurality of lipid nanoparticles comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a nucleic acid segment; as well as methods for delivering a nucleic acid segment comprising administering a plurality of lipid nanoparticles comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a nucleic acid segment.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
The present disclosure relates to an mRNA molecule encoding a polypeptide comprising an hMPV F protein, or an immunogenic fragment thereof, and a lumazine synthase (LuS) capable of multimerising to form a nanoparticle. Further aspects of the disclosure relate to compositions comprising the mRNA molecule and their use as a vaccine in the prevention of infectious diseases, including those caused by hMPV and RSV.
The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of cancer, wherein the EGFR TKI is administered in combination with an inhibitor of c-MET.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Antibodies for medical purposes; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Antibodies for medical purposes; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines
88.
COMPOUNDS AND METHODS FOR REDUCING ARHGEF6 EXPRESSION
Provided are oligonucleotides, polynucleotide conjugates, and compositions and populations comprising the same, as well as methods and uses thereof for reducing the amount or activity of Rho guanine nucleotide exchange factor 6 (ARHGEF6) RNA in a cell or animal, and in certain instances reducing the amount of ARHGEF6 protein in a cell or animal Such oligonucleotides, polynucleotide conjugates, and compositions and populations, methods and uses are useful to treat kidney diseases or conditions. In particular, such oligonucleotides, polynucleotide conjugates, and compositions and populations, methods and uses are useful to treat chronic kidney disease, such as diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), renal hypertension (HTN), IgA nephropathy / Berger's disease (IgAN), rapidly progressive glomerulonephritis (RPGN) and systemic lupus erythematosus (SLE).
The present disclosure relates to CD22 binding molecules, such as anti-CD22 antibodies, for the treatment of cancer, and related antibody-drug conjugates.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
ABSTRACT: Disclosed herein are compounds of Formula (I): [Image disponible dans le document PDF, Image available in the PDF document] and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same. The compounds and pharmaceutically acceptable salts of the disclosure may be useful in treating a JAK1-related disorder such as Type 1 diabetes, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, COPD, vitiligo and alopecia areata.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The disclosure relates to methods and compositions for the treatment of systemic lupous erythematosus (SLE). Specifically, the disclosure relates to methods comprising administering to a subject a type I IFN receptor inhibitor.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
The specification relates to the administration of small molecule, once-daily, oral glucagon-like peptide-1 receptor agonists for the treatment in a subject in need thereof.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
The specification relates to the administration of small molecule, once-daily, oral glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The specification relates to the administration of small molecule, once-daily, oral glucagon-like peptide-1 receptor agonists for the for chronic weight management and the treatment of obesity and overweight.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The specification relates to the co- administration of small molecule, once-daily, oral glucagon-like peptide-1 receptor agonists and SGLT-2 inhibitors.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
The specification relates to the co- administration of small molecule, once-daily, oral glucagon-like peptide-1 receptor agonists and PCSK9 inhibitors.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
The specification relates to the administration of small molecule, once-daily, oral glucagon-like peptide-1 receptor agonists for the treatment of inflammatory disorders and autoimmune disorders.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
Provided are compositions of a multi-specific T-cell engager comprising a claudin 18.2 (CLDN18.2) binding site and a T cell binding site, in combination with a checkpoint inhibitor agent and/or one or more chemotherapy agent(s), and methods of use therefor. Methods for treating a patient having a CLDN18.2-expressing solid tumor with a bispecific T cell engager (BsTCE), comprising a first domain that binds to CLDN18.2 and a second domain that binds to a T cell, in combination with a checkpoint inhibitor agent and/or one or more chemotherapy agent(s) are disclosed. Also provided are pharmaceutical compositions comprising provided combinations, such pharmaceutical composition combinations for use in the treatment of a CLDN18.2-expressing cancer, and the use of such pharmaceutical composition combinations for the manufacture of a medicament for treating a CLDN18.2-expressing cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
